Kodiak Sciences (KOD) Competitors

Kodiak Sciences logo
$100.73 -10.46 (-9.41%)
Closing price 04:00 PM Eastern
Extended Trading
$100.96 +0.23 (+0.23%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KOD vs. INSM, UTHR, INCY, BNTX, and ALNY

Should you buy Kodiak Sciences stock or one of its competitors? Kodiak Sciences's main competitors and comparable companies include Insmed (INSM), United Therapeutics (UTHR), Incyte (INCY), BioNTech (BNTX), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kodiak Sciences compare to Insmed?

Kodiak Sciences (NASDAQ:KOD) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Kodiak Sciences has a net margin of 0.00% compared to Insmed's net margin of -39.85%. Insmed's return on equity of -96.38% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -287.64% -87.83%
Insmed -39.85%-96.38%-32.55%

In the previous week, Kodiak Sciences had 5 more articles in the media than Insmed. MarketBeat recorded 13 mentions for Kodiak Sciences and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat Kodiak Sciences' score of 0.54 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kodiak Sciences has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A
Insmed$606.42M43.83-$1.28B-$2.82N/A

Kodiak Sciences currently has a consensus price target of $109.00, suggesting a potential downside of 1.97%. Insmed has a consensus price target of $196.52, suggesting a potential upside of 62.20%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

Kodiak Sciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

89.1% of Kodiak Sciences shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Insmed beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$3.18B7.91$1.33B$26.5022.31
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A

United Therapeutics presently has a consensus target price of $676.40, indicating a potential upside of 14.42%. Kodiak Sciences has a consensus target price of $109.00, indicating a potential downside of 1.97%. Given United Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe United Therapeutics is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

United Therapeutics has a net margin of 38.61% compared to Kodiak Sciences' net margin of 0.00%. United Therapeutics' return on equity of 19.18% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics38.61% 19.18% 17.07%
Kodiak Sciences N/A -287.64%-87.83%

United Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

In the previous week, United Therapeutics had 16 more articles in the media than Kodiak Sciences. MarketBeat recorded 29 mentions for United Therapeutics and 13 mentions for Kodiak Sciences. United Therapeutics' average media sentiment score of 0.96 beat Kodiak Sciences' score of 0.54 indicating that United Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
13 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

United Therapeutics beats Kodiak Sciences on 13 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Incyte?

Kodiak Sciences (NASDAQ:KOD) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Incyte has a net margin of 6.71% compared to Kodiak Sciences' net margin of 0.00%. Incyte's return on equity of 7.92% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -287.64% -87.83%
Incyte 6.71%7.92%6.12%

In the previous week, Incyte had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 18 mentions for Incyte and 13 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.54 beat Incyte's score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Incyte
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral

Kodiak Sciences has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Incyte has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Kodiak Sciences presently has a consensus price target of $109.00, indicating a potential downside of 1.97%. Incyte has a consensus price target of $132.86, indicating a potential upside of 9.83%. Given Incyte's higher probable upside, analysts plainly believe Incyte is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Incyte has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A
Incyte$6.01B4.10$1.29B$1.8864.35

Summary

Incyte beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to BioNTech?

Kodiak Sciences (NASDAQ:KOD) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Kodiak Sciences had 4 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for Kodiak Sciences and 9 mentions for BioNTech. Kodiak Sciences' average media sentiment score of 0.54 beat BioNTech's score of 0.38 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kodiak Sciences has higher earnings, but lower revenue than BioNTech. Kodiak Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A
BioNTech$2.42B8.94-$1.29B-$6.85N/A

Kodiak Sciences has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Kodiak Sciences has a net margin of 0.00% compared to BioNTech's net margin of -61.39%. BioNTech's return on equity of -4.51% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -287.64% -87.83%
BioNTech -61.39%-4.51%-3.96%

Kodiak Sciences presently has a consensus target price of $109.00, indicating a potential downside of 1.97%. BioNTech has a consensus target price of $122.27, indicating a potential upside of 42.83%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
BioNTech
1 Sell rating(s)
5 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.68

Summary

Kodiak Sciences and BioNTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Alnylam Pharmaceuticals presently has a consensus price target of $305.86, suggesting a potential upside of 85.33%. Kodiak Sciences has a consensus price target of $109.00, suggesting a potential downside of 1.97%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Kodiak Sciences' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals52.85% 155.33% 44.81%
Kodiak Sciences N/A -287.64%-87.83%

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 13 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.54 beat Alnylam Pharmaceuticals' score of 0.44 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
2 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$3.71B5.95$313.75M$19.268.57
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A

Alnylam Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Kodiak Sciences on 13 of the 16 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KOD vs. The Competition

MetricKodiak SciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6.80B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E RatioN/A24.2434.3430.11
Price / SalesN/A14.858.005.34
Price / CashN/A21.8921.0222.34
Price / Book33.924.354.763.85
Net Income-$229.97M-$24.19M$3.52B$393.14M
7 Day Performance-5.95%-7.26%-5.34%-4.53%
1 Month Performance17.47%-4.96%-3.61%-5.86%
1 Year Performance416.30%-2.87%0.01%-7.78%

Kodiak Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KOD
Kodiak Sciences
2.3576 of 5 stars
$100.73
-9.4%
$109.00
+8.2%
+469.9%$6.80BN/AN/A124
INSM
Insmed
3.3329 of 5 stars
$118.03
+1.7%
$196.52
+66.5%
-37.3%$25.74B$606.42MN/A1,664
UTHR
United Therapeutics
4.6582 of 5 stars
$587.57
+0.9%
$676.40
+15.1%
+26.8%$25.20B$3.18B22.171,400
INCY
Incyte
2.9477 of 5 stars
$120.30
-1.3%
$132.86
+10.4%
+16.1%$24.42B$5.14B63.732,844
BNTX
BioNTech
3.9931 of 5 stars
$87.81
+0.3%
$122.27
+39.2%
-17.0%$22.04B$3.25BN/A7,807

Related Companies and Tools


This page (NASDAQ:KOD) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners